^
Association details:
| Biomarker: | EGFR mutation + KIR3DL1 rs199822561 |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
Published date:
07/29/2023
Excerpt:
We sequenced tumor exomes from 135 lung cancer patients (79 with EGFR-wildtype (WT), 56 with EGFR-mutant tumors) enrolled in the ALCAPONE trial...Similarly, three polymorphisms in the KIR3DL1 gene: rs199822561 (c.1277 T > C, p.(Ile426Thr)), rs200821495 (c.1279 T > A, p.(Leu427Met)), and rs72629105 (c.1286C > T, p.(Thr429Met)), were associated with a decreased PFS only in patients with EGFR-mutant tumors treated with an EGFR TKI (HR = 2.79 [1.26–6.14]; p = 0.008; Fig. 1A).
DOI:
https://doi.org/10.1186/s12943-023-01829-4
Trial ID:
